Mechanism-of-action video that stays on label
Device animation drifts off label in one unreviewed shot. An intended-use-first storyboard method and a clearance-linked review checklist that catches it.
A mechanism-of-action animation almost never goes off label in the voiceover. The script gets four rounds of regulatory review and comes back clean. It goes off label in shot nine, where an artist needed a visual for a word and invented one, and nobody on the review call had a way to say what that shot was claiming.
That is the structural problem with device animation. Your regulatory reviewer is fluent in sentences and your storyboard is not made of sentences. The Indications for Use statement is a paragraph of careful, bounded language, and the video is 400 frames of implication. Unless the storyboard is built to be read against the clearance, the two documents never actually meet.
The language layer, first
Get this right before anything visual, because it is the cheapest fix and the most common miss.
A device cleared through 510(k) is cleared, not approved. Devices that go through premarket approval are approved. Writing "FDA-approved" over a cleared device is a factual error about your own regulatory status, and it is the sort of error that turns up in a competitor's complaint rather than in your own audit. It shows up in three places: the voiceover, the end card, and the video description that marketing writes after the file is locked and nobody reviews.
The second language rule is that your promotional claims live inside the cleared Indications for Use. Promotion beyond that intended use is off-label promotion regardless of format, and a video is promotional labeling in exactly the way a brochure is. There is no lighter standard because it moves.
Where animation actually drifts
Seven modes account for nearly all of it. Every one of them is a picture, not a sentence.
- Anatomy drift. The animation shows the device acting on a site the indications do not cover, usually because the artist needed a clearer cross-section and picked a more photogenic one.
- Population drift. A pediatric patient, or an obviously pregnant one, in a video for a device indicated in adults. Casting is a claim about the indicated population.
- Mechanism drift. The animation depicts a biological effect the labeling does not describe. Cells visibly regenerating, bacteria visibly dying, inflammation visibly receding. If the clearance does not say the device does that, the animation must not show it.
- Extent drift. A cutaway showing depth of penetration, coverage area, or dose distribution that no supporting data establishes. Cutaways feel like diagrams and read like evidence.
- Time drift. Compression that implies speed. Three seconds of animation standing in for a twelve-week process, with no time indicator on screen, is a claim about onset.
- Comparative drift. Any split screen against "conventional treatment" or an unnamed competitor geometry. A comparative visual is a comparative claim and needs head-to-head data behind it.
- Workflow drift. The sequence skips a step the instructions for use require, or omits a required accessory, because the full sequence was boring. You have now animated an off-label technique.
Notice that none of these are caught by reading the script. That is the whole point.
Intended-use-first storyboarding
The method is simple and it changes the review conversation completely.
Put the verbatim Indications for Use at the top of the storyboard document. Not a summary, not marketing's paraphrase. The actual statement, copied.
Break it into numbered clauses. A typical IFU decomposes into six to twelve: the device type, the intended user, the patient population, the anatomical site, the condition, the setting, and any explicit limitations. Number them.
Make every frame cite a clause. Each storyboard frame carries a clause number in its metadata line. A frame that cites nothing is not a frame yet. It is either cut, redrawn until it depicts something the IFU covers, or moved to a deliverable that is not promotional and carries its own separate rules.
Add a second caption line per frame: what a viewer concludes. Marketers write what the frame shows. Reviewers argue about what it implies. Writing both lines forces the argument to happen at the storyboard stage, where a change costs an hour, instead of at the final review, where it costs a re-render and a calendar slip.
Review the storyboard before generating anything. This is the sequencing change that does the work. The AI storyboarding guide covers building the boards; the discipline specific to devices is that regulatory signs the board, not just the script.
Then build. The explainer video generator handles the structured narration-plus-visual spine, key frames come out of text to image against the approved boards, and everything assembles on a re-renderable timeline in the video editor. The 480p preview pass is free with a short per-user cooldown, which is exactly enough to put a moving cut in front of the review committee before you spend credits on the final export. That export is charged once regardless of clip count, so the cost of another review round is calendar time rather than budget, which is the correct incentive.
For the surrounding B2B structure, explainer video production for complex B2B covers the parts that are not regulatory.
The clearance-linked review checklist
Run this against the storyboard, then again against the final render. Ten rows, named owners, no ambiguity about who decides.
| Check | The question | Owner |
|---|---|---|
| Regulatory status language | Does every mention use cleared or approved correctly for this pathway? | Regulatory |
| Clause mapping | Does every frame cite an IFU clause? | Marketing and Regulatory |
| Anatomy | Is every depicted site inside the indicated anatomy? | Clinical |
| Population | Does every depicted patient match the indicated population? | Clinical |
| Mechanism | Is each animated biological effect described in the labeling? | Clinical and Regulatory |
| Extent and dose | Is depicted depth, coverage, or distribution supported? | Clinical |
| Time | Does any compressed sequence imply an onset claim? Is there a time super? | Regulatory |
| Comparative | Any side-by-side or "versus conventional" visual? Is there head-to-head data? | Regulatory |
| Workflow | Does the sequence match the IFU steps and required accessories? | Clinical |
| Market | Is this cut approved for the market it will run in? | Regulatory |
The last row catches the failure that scales worst. A device's indications are not identical across markets, and one global MOA video pushed to every regional site is how a claim that is fine in one jurisdiction ends up running in one where it is not. Build the market variants as separate approved cuts sharing a common EDL, with the IFU super and end card swapped per market. That is a card change on one timeline, not a rebuild.
Production choices that reduce regulatory risk
Choose stylized over photoreal, deliberately. A clearly stylized 3D render is honest about being a diagram. A photoreal render of tissue implies you are showing what actually happens in a body, which is a claim about observed reality that your data almost certainly does not support at that resolution. Photorealism in MOA animation buys you a small aesthetic gain and a large evidentiary problem.
Super the abstraction. A line reading "Illustrative representation. Not actual anatomy or clinical footage" costs you one frame and removes an entire category of argument. Where the animation compresses time, say so on screen.
Never generate a clinician or patient who reads as a real case. Generated people are fine as neutral illustrative figures. The moment framing, captioning, or context suggests this is a patient who was treated, you have produced a testimonial without a patient, which is a different and worse problem.
Do not let field teams re-cut approved assets. In practice this is a common source of off-label device video. A regional sales manager trims the 3-minute MOA to 45 seconds for a conference booth and cuts the limitation super along with the boring middle. Prevent it by shipping the cutdowns yourself: a 3-minute, a 90-second, a 45-second, and a silent booth loop, all approved, all from the same timeline. If the approved short version exists, nobody makes an unapproved one. AI content governance for brands covers building the asset library that makes this enforceable, and content approval workflows that don't stall covers keeping the review loop from becoming the reason people go around it.
Freeze and log. Store the approved render, the storyboard with its clause citations, and the timeline that produced it, together. When someone asks in eighteen months whether the video on the product page is the reviewed one, you want to answer with a file rather than a recollection.
FAQ
Can we animate a mechanism that is well established in the literature but not in our labeling?
Not in promotional material for your device. The literature may describe a physiological process accurately, and depicting your device causing that process is still a claim about your device. Published science supports scientific exchange, which is a different channel with different rules. Ask regulatory which bucket the deliverable belongs to before you board it, because the answer changes the whole build.
How do we handle an animation for a device with multiple cleared indications?
Build one video per indication rather than one video covering all of them. Combined videos blur which claim attaches to which use, and the blur is exactly what a reviewer will flag. Shared assets across the set keep the cost of the second and third video low, since the environment, style, and device model are already built.
Is a generated voiceover acceptable for regulated device content?
The narration is reviewed as script and as delivery, and a synthesized read is neither better nor worse than a booked one on that axis. What matters more is that a generated voice makes late script changes cheap, which is why teams that use one tend to end up with fewer unreviewed compromises in the final cut. Review the rendered audio, not the script document.
Where should the limitation and risk information live in a short cut?
On screen, legible, for long enough to read at the distance the video will be watched from. A booth loop viewed from ten feet away and a 9:16 phone cut have different legibility floors, and a super sized for one fails at the other. Check each cut on the surface it will actually run on, not on an editing monitor.